| Name | Title | Contact Details |
|---|
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
Diosynth Biotechnology is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Carolus Therapeutics is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pacific Biosciences is developing an environment in which scientists can seamlessly integrate multiple data types from multiple sources and deploy advanced bioinformatics methods to elucidate the complexity of living systems. Therefore, we are committed
3 Prime is a Aston, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.